Company news
Medicenna Therapeutics Corp. news in 2020
Medicenna Therapeutics Corp.'s news releases, calls and decks from 2020, newest first.
Medicenna to Present at Raymond James Human Healthcare Innovation Conference
June 11, 2020
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th
June 3, 2020
Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020
May 29, 2020
Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020
May 29, 2020
Medicenna Announces March 31, 2020 Year-End Results
May 15, 2020
Medicenna Announces Upcoming Presentations at the ASCO Annual Meeting
May 4, 2020
Medicenna Announces Full Exercise of Over-Allotment Option as Part of $40.25 Million Public Offering
April 15, 2020
Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study
March 25, 2020
Medicenna Announces Closing of Public Offering of $35 Million
March 17, 2020
Medicenna Announces Intention to File Final Short Form Prospectus
March 12, 2020
Medicenna Announces Pricing of $35 Million Overnight Marketed Offering of Common Shares
March 4, 2020
Medicenna Announces Overnight Marketed Offering of Common Shares
March 3, 2020
Medicenna Reports Third Quarter Fiscal 2020 Financial Results
February 13, 2020
President and CEO of Medicenna Therapeutics Corp., Dr. Fahar Merchant, is Featured on The Stock Day Podcast
January 21, 2020
Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control Arm
January 13, 2020
Medicenna Receives $1.3 Million Through Early Warrant Exercises
January 8, 2020